Supplementary Tables. Real world assessment of myelodysplastic syndrome: Japanese claims data analysis

Supplementary Table 1. Inflation adjustment based on calendar year averages.

Supplementary Table 2. Nominal cost outcomes up to 3-year follow-up (LS-means and p-value were adjusted for all baseline comorbidities)

Supplementary Table 3. Nominal cost outcomes up to 3-year follow-up among HSCT groups

Supplementary Table 4. Additional patient baseline characteristics overall and by treatment category

Supplementary Table 5. Baseline characteristics for ESA and AZA patients who had transfusion within the first year of follow-up

Supplementary Table 6. Median cost (USD) for each treatment group over 3-years and stratified by follow-up month

Supplementary Table 7. Baseline characteristics for patients with incremental TD

Supplementary Table 8. Health care resource utilization stratified by follow-up month